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Abstract
Renal elimination and the resulting clearance of perfluorooctanoic acid (PFOA) from the serum 
exhibit pronounced sex differences in the adult rat. The literature suggests that this is largely due 
to hormonally regulated expression of organic anion transporters (OATs) on the apical and 
basolateral membranes of the proximal tubule cells that facilitate excretion and reabsorption of 
PFOA from the filtrate into the blood. Previously developed PBPK models of PFOA exposure in 
the rat have not been parameterized to specifically account for transporter-mediated renal 
elimination. We developed a PBPK model for PFOA in the male and female rat to explore the role 
of Oat1, Oat3, and Oatp1a1 in sex-specific renal reabsorption and excretion of PFOA. 
Descriptions of the kinetic behavior of these transporters were extrapolated from in vitro studies 
and the model was used to simulate time-course serum, liver, and urine data for intravenous (IV) 
and oral exposures in both sexes. Model predicted concentrations of PFOA in the liver, serum, and 
urine showed good agreement with experimental data for both the male and female rat indicating 
that in vitro derived physiological descriptions of transporter-mediated renal reabsorption can 
successfully predict sex-dependent excretion of PFOA in the rat. This study supports the 
hypothesis that sex-specific serum half-lives for PFOA are largely driven by expression of 
transporters in the kidney and contributes to the development of PBPK modeling as a tool for 
evaluating the role of transporters in renal clearance.
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Perfluorinated compounds (PFCs) have been used since the 1950’s in a variety of industrial 
applications and consumer products. Perfluorooctanoic acid (PFOA) is among one of the 
most well studied members of this class of compounds (ATSDR, 2009) and is frequently 
found in oil, stain, grease, and water repellent coatings on carpets, textiles, leather, and 
paper (ATSDR, 2009). PFOA is particularly environmentally and biologically persistent due 
to its eight-carbon backbone, strong carbon-fluorine bonds, and metabolic stability (Calafat 
et al., 2007; Bartell et al., 2010). Despite recent reductions in manufacturing, PFOA has 
been identified as a ‘contaminant of emerging concern’ by the U.S. Environmental 
Protection Agency (EPA) due to its frequent detection in water systems across the United 
States (USEPA, 2008; USEPA, 2009; Bartell et al., 2010) as well as in the blood of the 
general U.S. population (Calafat et al., 2006; Calafat et al., 2007; Olsen et al., 2007; Olsen 
et al., 2012; USEPA, 2014a).
Epidemiological studies of occupational and community exposure to PFCs indicate 
associations between blood serum levels of PFOA and high cholesterol, other liver effects 
including increased liver enzymes and decreased bilirubin levels, chronic kidney disease, 
and early menopause (Olsen et al., 2000; Olsen et al., 2007; Sakr et al., 2007a; Sakr et al., 
2007b; Vaughn et al., 2013; USEPA, 2014b). In rodent studies, PFOA has resulted in body-
weight changes, developmental effects, liver effects, and decreased serum total cholesterol 
(Ikeda et al., 1985; Kawashima et al., 1995; Butenhoff et al., 2004; Guruge et al., 2006; Lau 
et al., 2006; Cui et al., 2009).
The pharmacokinetics of PFOA are well studied in rats. PFOA is known to be well absorbed 
in the gastrointestinal tract, highly bound in the serum albumin, not metabolized, and 
excreted unchanged primarily via the kidneys (Johnson et al., 1979; Vanden Heuvel et al., 
1991). PFOA reaches steady-state in the serum very rapidly with daily dosing, but is 
eliminated slowly (Bartell et al., 2010). The serum half-life for PFOA is estimated to be 
between four and six days in the male rat and between two and four hours in the female rat 
(Kemper, 2003). In contrast, the serum half-life for PFOA in humans has been estimated to 
be between 2.3 and 3.8 years (Olsen et al., 2007; Bartell et al., 2010). This sex and species 
specificity in serum half-life is hypothesized to be due to hormonally-regulated, saturable 
renal reabsorption of PFOA via organic anion transporters (OATs) expressed on the apical 
and basolateral membranes of the proximal tubule cells (Kudo et al., 2002; Andersen et al., 
2006; Nakagawa et al., 2007). The rat model described here uses in vitro to in vivo 
extrapolation (IVIVE) to incorporate physiological descriptions of these transporters to 
predict sex specific renal clearance of PFOA in the adult rat.
Oat1 (Slc22a6) and Oat3 (Slc22a8) are expressed most highly in the proximal tubule cells of 
the rat kidneys and are localized to the basolateral membrane (Buist et al., 2002; Weaver et 
al., 2010). An extensive list of diverse substrates have been identified for Oat1, including 
PFOA. Oat3 has also been shown to be capable of PFOA transport (Nakagawa et al., 2007) . 
Together, these basolateral membrane transporters translocate PFOA from the blood into the 
proximal tubule cells and facilitate renal secretion. Oatp1a1 (Slco1a1) is expressed on the 
Worley and Fisher Page 2













apical membrane of the proximal tubule cells in the rat and has been shown to transport 
PFOA from the urine back into the proximal tubule cells, thereby facilitating renal 
reabsorption (Weaver et al., 2010). The expression of these transporters is known to be sex-
hormone regulated and have sex specific expression patterns in the adult rat (Buist et al., 
2002). OATs are responsible for the movement of many pharmaceuticals and chemicals in 
the kidney. Sex-specific clearance and biological half-life has been demonstrated for several 
substrates of OATs including p-aminohippurate (PAH) (Reyes et al., 1998), zenarestat 
(Tanaka et al., 1991; Morris et al., 2003)), S-pentachlorophenyl-N-acetyl-L-cysteine (Smith 
and Francis, 1983), carnitine (Carter and Stratman, 1982), nilvadipine metabolite (M3) 
(Terashita et al., 1995) and 1-aminocyclohexanecarboxylic acid (Anton et al., 1986).
One other PBPK model for PFOA administration in the adult rat exists in the published 
literature (Loccisano et al., 2012). This model describes saturable reabsorption of PFOA 
from the filtrate compartment back into the kidney compartment via a single transporter with 
transporter maximum (Tm) and affinity constant (Kt) based on in vitro data describing 
Oatp1a1 uptake of PFOA. While this model was able to successfully describe PFOA 
kinetics in the adult rat, the information necessary to scale in vitro measurements of 
transporter activity to in vivo values for the transporters involved in both the excretion and 
renal reabsorption was not available at the time (Loccisano et al., 2012). The model 
described here applies recent in vitro data to expand upon the existing model by including 
physiological descriptions of both basolateral and apical membrane transporters in order to 
describe the sex specific kinetics of excretion and reabsorption in the kidneys. This 
evidence-based model confirms the findings of prior hypothesis-driven modeling efforts by 
showing that saturable reabsorption is necessary to achieve a consistent description of the 
experimental data. Further, it supports the hypothesis that sex-specific serum half-lives for 
PFOA are largely driven by expression and activity of transporters in the kidney and 
contributes to the development of PBPK modeling as a tool for evaluating the role of 
transporters in renal clearance.
Materials and Methods
Key Pharmacokinetic Studies in the Male and Female Rat
Pharmacokinetic data for PFOA in the adult rat were available for both oral gavage and 
intravenous (IV) dosing routes (Kemper, 2003; Kudo et al., 2007) for male and female 
Sprague-Dawley and Wistar rats. Datasets reporting PFOA concentrations in serum, urine, 
feces, and liver tissue following single IV and oral administration were used for 
development and evaluation of the model (Table 1).
For IV dosing, two data sets were available. In the first, four adult male and four adult 
female Sprague-Dawley rats were administered 1.0 mg/kg body weight [carbonyl-14C] 
ammonium perfluorooctanoate (14C-PFOA) via a surgically implanted jugular vein cannula 
(Kemper, 2003). In male rats, whole blood samples were collected from the cannula or from 
the tail vein pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours post-dose, at 24-hour 
intervals through 192 hours, and then at 48-hour intervals from 192 through 528 hours. In 
female rats, whole blood samples were collected from the cannula or the tail vein pre-dose 
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and at 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, and 72 hours post-dose. Serum samples were 
analyzed for 14C-PFOA by liquid scintillation counting (LSC).
In the second IV dosing study, nine-week old male Wistar rats (four animals per dose group) 
were administered an IV dose of either 0.041 or 16.56 mg/kg body weight [1-14C] PFOA 
(Kudo et al., 2007). Whole blood samples were collected from the vena cava two hours after 
injection, after which animals were euthanized and tissue samples, including liver, kidney, 
intestine, testis, spleen, fat, heart, lung, brain, and stomach were collected. Serum and tissue 
samples were analyzed for 14C-PFOA by LSC.
One extensive dataset was available for oral dosing of PFOA and included measurement of 
PFOA in urine, feces and serum (Kemper, 2003). Four male and four female Sprague-
Dawley rats per dose group were administered 14C-PFOA in a water vehicle via oral gavage 
at doses of 0.1, 1.0, 5.0 or 25.0 mg/kg body weight. For male rats, whole blood samples 
were collected from a surgically implanted jugular vein cannula or from the tail vein pre-
dose and at 0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours post-dose, at 24-hour intervals through 
192 hours, and then at 48-hour intervals from 192 through 528 hours. In female rats, whole 
blood samples were collected from the cannula or tail vein pre-dose at 0.25, 0.5, 1, 2, 4, 8, 
12, 16, 24, 36, 48, 72, and 96 hours post-dose.
In a separate set of experiments (Kemper, 2003), four adult male and four adult female 
Sprague-Dawley rats per dose group were administered 14C-PFOA in a water vehicle via 
oral gavage at doses of 1.0, 5.0, or 25.0 mg/kg body weight. Following dosing, rats were 
housed individually in glass metabolism cages that allowed for collection of urine, feces, 
expired air, and volatile organics. For male rats, urine and feces were collected at 4, 8, 12, 
and 24 hours post-dose, and at 24-hour intervals through 336 hours. For female rats, urine 
and feces were collected at 4, 8, 12, and 24 hours post-dose, and at 24-hour intervals through 
168 hours. Serum, urine, and feces samples were analyzed for 14C-PFOA by LSC.
Rat Model Development
A biologically-based compartmental model for PFOA in monkeys (Andersen et al., 2006) 
and a PBPK model for PFOA in rats (Loccisano et al., 2012) were used as a starting point to 
expand upon descriptions of transporter-mediated renal reabsorption. The model described 
here builds on this prior work using recently published data for in vitro to in vivo 
extrapolation in order to include physiologically-based descriptions of the basolateral and 
apical transporters associated with renal excretion and renal reabsorption.
PBPK Model Structure for PFOA
The model contains compartments for plasma, liver, stomach, small intestines, kidney 
serum, kidney proximal tubule cells, kidney filtrate, and a lumped compartment representing 
the rest of the body tissues (Figure 1). In contrast to previous models, a three-compartment 
kidney was used to describe renal excretion and reabsorption. PFOA is moved from the 
kidney blood into the filtrate in the lumen of the proximal tubule via glomerular filtration. 
PFOA in the filtrate is excreted in the urine via first-order rate constant kurine, or actively 
translocated into the proximal tubule cells via apical transporters. This non-linear process 
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was described using Michaelis-Menten parameters, Vmax_apical and Km_apical. PFOA in 
the kidney blood is actively translocated into the proximal tubule cells by basolateral 
transporters, again described using Michaelis-Menten parameters, Vmax_baso and 
Km_baso, and diffusion into and out of the proximal tubule cells via a first-order passive 
diffusion rate constant, kdif. Studies of cellular uptake of PFOA by OATs and their role in 
mediating renal reabsorption have suggested that there may be an efflux pathway that pumps 
intracellular PFOA from the proximal tubule cells back into systemic circulation (Yang et 
al., 2010). The model described this movement via a first-order rate constant, kefflux.
PFOA oral bolus gavage was described using a stomach compartment. Absorption of PFOA 
in the GI tract was described in the stomach and small intestines. PFOA absorbed in the GI 
tract is carried to the liver in the serum. PFOA administered intravenously enters directly 
into systemic circulation. PFOA is excreted from the system in the bile, urine, and feces.
Model code was written and simulations were performed using AcslX modeling software 
(AEgis Technologies, Huntsville, AL, version 3.0.2.1). Model code is available in the 
supplementary materials.
Model Parameterization
Physiological Parameters—Physiological parameters for the rat are shown in Table 2. 
Body weights reported in each study were used for simulations. For experiments with more 
than one animal per dose group, average body weight was used. Fractional tissue volumes, 
cardiac output, fractional plasma flow, and glomerular filtration rates were obtained from 
the literature and scaled to body weight (Table 2). PFOA does not partition into the red 
blood cells. This was accounted for in the model by adjusting blood flow rates to plasma 
flow rates by multiplying blood flow by 1 – hematocrit.
Chemical Specific Parameters—Chemical specific parameters used in the model are 
shown in Table 3 and a few are explained in detail in the following sections.
Free Fraction: More than 90% of PFOA is bound to the serum albumin in rat blood (Han et 
al., 2003). Only the free fraction of PFOA is available for distribution. This was accounted 
for in the model using a free fraction constant (Free) that was multiplied by the 
concentration of PFOA moving into and out of each compartment such that only the 
unbound PFOA was able to partition into the compartment, be moved from one 
compartment to another via transporters, or be excreted from the body in the urine and feces. 
This parameter was fit to experimental data (see Model Calibration). The available kinetic 
data for PFOA in rats all reported total PFOA concentrations in the serum. In order to 
compare model predicted serum concentrations to the serum concentrations measured in 
these studies, free PFOA was translated back into total PFOA to generate predicted serum 
concentrations curves.
Uptake and Elimination: A two-compartment GI tract was used to describe uptake of 
PFOA administered via oral gavage. Uptake in the stomach was described using a first-order 
rate constant, k0c. Uptake in the small intestine was described using a first-order rate 
constant, kabsc. Elimination was described via the urine, feces, and bile. A first-order 
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urinary elimination rate, kurinec, was used to describe the excretion of PFOA from the 
filtrate compartment via the urine. The amount of unabsorbed dose to appear in the feces 
was described using a first-order rate constant, kunabsc. Experimental evidence suggests 
that PFOA is susceptible to biliary excretion (Kudo et al., 2007), however, both males and 
females are thought to excrete <1% of the administered dose via this route (Nakagawa et al., 
2007). A first-order biliary excretion rate, kbilec, was used to account for PFOA excreted 
into the feces via the bile. First order rate constant, keffluxc, was used to account for the 
efflux pathway that pumps intracellular PFOA from the proximal tubule cells back into 
systemic circulation. Kbilec, k0c, kabsc, kunabsc, keffluxc, and kurinec were fit to 
experiment data (see Model Calibration) and scaled to body weight (BW0.25).
Tissue Partitioning: Tissue: plasma partition coefficients for PFOA in the kidney (PK), 
liver (PL), and rest of body (PR) were estimated from plasma and tissue data collected by 
Kudo et al. (2007). Male Wistar rats were administered a single IV dose of either 0.041 
mg/kg body weight or 16.56 mg/kg body weight [1-14C] PFOA and serum and tissue 
samples were collected two hours post-dose. Concentrations measured in the serum, kidney, 
liver, and remaining body tissues following the low dose administration were used to 
calculate partition coefficients for the model. Partition coefficients used in this model are 
consistent with those used in previous modeling efforts (Loccisano et al., 2012).
Transport in the kidney compartment: In vitro to in vivo extrapolation was used to derive 
parameters describing transport of PFOA in the kidney compartment. Michaelis-Menten 
parameters describing Oat1 and Oat3 were calculated from data reported in in vitro studies 
that measured [14C] PFOA uptake by rat OATs expressed in human embryonic kidney 
(HEK293) cells (Nakagawa et al., 2007). Measurements of Vmax for Oat1 and Oat3 uptake 
of [14C] PFOA were averaged (Vmax_baso_invitro = 393.45 pmol/mg protein/min) and 
translated to in vivo values (Vmax_baso) by multiplying with a relative activity factor 
(RAFbaso) and an estimated mass of proximal tubule cells (protein) based on an estimated 
60 million proximal tubule cells per gram kidney (Hsu et al., 2014). Relative activity factor 
information for the basolateral membrane transporters was not available in the literature, so 
this parameter (RAFbaso) was fit to experimental data (as described in the Model 
Calibration section of the text). The km value (Km_baso) was calculated by averaging the 
Km values reported for Oat1 and Oat3 uptake of [14C] PFOA (Yamada et al., 2007) and 
used directly in the model.
Michaelis-Menten parameters for Oatp1a1 were calculated from values measured in in vitro 
studies (Weaver et al., 2010) that explored the role of rat OATs in transporting 
perfluorinated carboxylates of different chain lengths. Measurement of Vmax for Oatp1a1 
uptake (Vmax_apical_invitro = 9,300 pmol/mg protein/min) of PFOA was translated to in 
vivo values (Vmax_apical) using a relative activity factor (RAFapi) and an estimated mass of 
proximal tubule cells (protein) based on an estimated 60 million proximal tubule cells per 
gram kidney (Hsu et al., 2014). The relative activity factor for the apical membrane 
transporter was not available in the literature, so this parameter (RAFapi) was fit to 
experimental data (as described in the Model Calibration section of the text). Km values 
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reported for Oatp1a1 uptake of PFOA (Weaver et al., 2010) were used directly in the model 
(Km_apical).
Model Calibration
Time course PFOA serum and urine data resulting from experiments (Kemper Experiment 1 
and Kemper Experiment 6a) in which adult male and female rats were administered a single 
oral gavage dose were used for calibration of the model and to fit parameter values for 
which data was not available (Table 1). Experiments (Kemper Experiment 6b) in which 
adult male rats were administered a single bolus IV dose of 1.0 mg/kg body weight 
(Kemper, 2003) were also used for calibration of the model and to fit parameter values for 
which data was not available (Table 1).
Parameter values that describe renal excretion and reabsorption (keffluxc, kurinec, RAFapi, 
and RAFbaso) and the extent of PFOA binding in the serum (Free) were optimized first 
using experimental data from the 14C-PFOA administration studies (Kemper, 2003; Kudo et 
al., 2007). To determine initial conditions, kurinec and Free were set to the values reported 
for the male rat in the Loccisano model (Loccisano et al., 2012), RAFapi and RAFbaso were 
set to the relative activity factor reported in the literature for human orthologues OAT1 and 
OAT3 (Yamada et al., 2007), and keffluxc was estimated based on the expectation that 
PFOA would be moved readily from the proximal tubule cells into systemic circulation. 
Parameter values were refined simultaneously to achieve a consistent description of the 
serum concentrations reported in Experiments 6a and 6b of the Kemper study. Initial and 
final calibrated values are shown in table 4.
Free, Keffluxc and kurinec were treated as non sex-specific and a single value was calibrated 
for the male and female rat models. RAFapi and RAFbaso were calibrated separately for the 
male and female rat models based on reports that these transporters are expressed at 
significantly higher levels in the male rat than in the female rat (Yang et al., 2009; Weaver 
et al., 2010).
Subsequently, parameter values that govern absorption of PFOA in the gastrointestinal tract 
(k0c, kabsc, kunabsc, and kbilec) were simultaneously optimized using experimental serum 
and urine data from oral administration studies (Kemper, 2003). Kabsc, kunabsc, and kbilec 
were initially set to those values reported in the Loccisano model (Loccisano et al., 2012). 
The initial value for k0c was estimated based on the expectation that more PFOA is 
absorbed in the small intestine than in the stomach. These parameter values were refined 
with the urine data reported in Experiment 1 of the Kemper study and with serum data 
reported in Experiment 6a of the Kemper study. These parameter values were treated as sex 
non-specific. Initial and final calibrated values are shown in table 4.
Model Evaluation
To evaluate the performance of the calibrated model, we simulated concentrations of total 
PFOA in serum, urine, and feces in the adult male and female rat, and liver tissue in the 
adult male rat resulting from IV and oral administration of PFOA using datasets not used in 
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model calibration. Descriptions of the experimental data used for model evaluation are 
presented in Table 1.
To determine the ability of the model to describe the pharmacokinetic behavior of PFOA in 
the adult rat, model simulations were evaluated for their ability to predict accurately peak 
concentrations, time-to-peak, as well as the shape of the concentration curves. The 
correspondence of individual data points to predicted values was evaluated visually to 
ensure that the model accurately predicted serum concentrations and the cumulative 
percentage of PFOA in the urine and feces over time. Predicted peak serum concentrations 
and the cumulative amount in the urine, and feces were compared to measurements in each 
study. The shape of the predicted serum, urine, and feces curves were examined in order to 
ensure that the predicted curves were consistent with the trends observed in the data. Given 
that feces is a very small contributor to PFOA excretion, less priority was given to feces 
predictions when evaluating the model.
In addition to qualitative model performance evaluation, model performance was evaluated 
quantitatively by calculating root mean squared errors (RMSE) for simulations of each 
experimental dataset with more than one experimental data point using the following 
equation,
where predicted is the predicted value, observed is the observed value, and n is the number 
of observed data points in the experimental dataset. Because RMSE is a relative parameter 
that exhibits dose effects, comparisons of RMSE values were made only for experiments 
conducted at the same dose.
Sensitivity Analysis
A time course sensitivity analysis was performed in order to determine the impact of each 
individual parameter on the outputs of the male and female rat models. Sensitivity 
coefficients were determined for the serum concentration resulting from a 1% change in the 
value of each parameter using the forward difference method. Sensitivity coefficients were 
normalized to the response variable and the parameter using the following equation,
where A is the serum concentration resulting from a 1% increase in the parameter value, B is 
the serum concentration resulting from the initial parameter value, C is the value of 
parameter increased by 1%, and D is the initial parameter value. Serum concentration 
predictions were run at simulations of single oral gavage administration of 1.0 and 25.0 
mg/kg body weight in the male and female rat. Positive sensitivity coefficients indicate a 
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direct association between the model output and the corresponding parameter. Negative 
sensitivity coefficients indicate an inverse correlation between the model output and the 
corresponding parameter. Parameters with absolute sensitivity coefficients greater than 0.1 
using serum concentrations from either of the simulated dose levels were identified as 
sensitive.
Exploration of the Impact of Dose on Renal Clearance
To evaluate the impact of PFOA dose on renal clearance and determine saturating doses of 
PFOA on the kidney transporters, simulations over a wide range of oral doses (0.1 – 1,000 
mg/kg body weight) were conducted for male and female rats. Time course data from each 
simulation was evaluated in order to determine the estimated half-life at each dose. The time 
at which the maximum serum concentration occurred, and the time at which one-half the 
maximum serum concentration was achieved after the maximum occurred were identified. 
The time required to reach the maximum concentration was subtracted from the time at 
which one half the maximum concentration was achieved in order to estimate the time the 
model predicted it would take for the peak serum concentration to be reduced by half. To 
evaluate the importance of the protein transporters in the kidney, simulations were repeated 
over the wide dose range of PFOA with the transporters effectively turned off 
(Vmax_baso_invitro = 0, Vmax_apical_invitro = 0).
Results
Model Calibration
IV Exposures—Model calibration with IV exposure data was conducted in the male rat 
only. This was due to a lack of experimental IV exposure data in the female rat. 
Comparisons of the predicted and measured serum concentrations resulting from exposure to 
1.0 mg/kg body weight IV exposure in the male rat can be seen in Figure 2. A moderate 
underestimation of the peak serum concentration was observed in the simulations. However, 
at later time points the predicted serum concentrations and the overall shape of the 
concentration curve show good agreement with the experimental data.
Oral Gavage Exposures—Comparisons of the simulated serum concentrations to 
measured serum concentrations following administration of male and female rats to a single 
oral dose of 1.0 mg/kg body weight showed good agreement with measured serum 
concentrations following calibration of model parameters. These comparisons are presented 
in Figure 3. A slight underestimation of the peak serum concentration was observed in 
simulations with the male rat model (Fig 3A). However, the overall shape of the predicted 
concentration curve closely matched the experimental data. Simulations of PFOA serum 
concentration with the female rat model were also in good agreement with the experimental 
data (Fig. 3C). Comparisons of the predicted and experimentally measured cumulative 
amount of PFOA in the urine following an oral dose of 1.0 mg/kg body weight can also be 
seen in Figure 3. The cumulative amount of PFOA in the urine predicted by the model 
accurately described the experimental data for this metric, both at individual time points and 
the overall shape of the curve, in the male and female rat model (Fig. 3B, 3D).
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Male Rat—In order to evaluate its predictive ability, the model was used to simulate time-
course data for IV and oral exposures in the male rat.
In the experiments reported by Kudo and colleagues male rats were administered a high 
(16.0 mg/kg body weight) or low (0.041 mg/kg body weight) bolus dose of PFOA via IV 
injection. Model simulations of serum and liver tissue concentrations were compared to the 
measured serum and liver concentrations resulting from each dose in the study (Figure 4). 
While data for only one time point is available for these experiments, good agreement is 
observed between predicted and measured serum concentrations at both high and low doses 
(Fig. 4A). The model slightly under predicted liver concentrations at the low dose, and 
slightly over predicted liver concentrations at the high dose (Fig. 4B). However, these 
discrepancies were within two-fold of the data. The authors of the experimental study (Kudo 
et al., 2007) reported that a larger portion of the administered PFOA was distributed to the 
serum, liver, and other tissues at the high dose compared to the low dose. The model 
successfully described this dose dependency.
Experimental time-course serum, urine, and feces data following oral administration of 0.1, 
5.0, and 25.0 mg/kg body weight (Kemper, 2003) were also available for model evaluation 
(Figure 5). Model simulations of serum concentration and the cumulative percent of the dose 
in the urine and feces for 5.0 and 25.0 mg/kg body weight doses were compared to the data 
reported in the study. Simulated serum concentrations showed good agreement with 
measured serum concentrations (Fig. 5A, 5C). A slight underestimation of the peak was 
observed at the 5.0 mg/kg body weight dose level, however, the overall shape of the 
predicted concentration curve closely match the experimental data at all doses. The 
cumulative amount of PFOA in the urine predicted by the model accurately described the 
experimental data for this metric, both at individual time points and the overall shape of the 
curve (Fig. 5B, 5D). The cumulative amount of PFOA in the feces predicted was over 
predicted by the model (data not shown).
Female Rat—The model was used to simulate time-course data for IV and oral exposures 
in the female rat.
In the available IV study (Kemper, 2003) female rats were administered a single bolus dose 
of 1.0 mg/kg body weight and serial serum samples were collected for 72 hours following 
the dose. Model simulations of serum concentrations were compared to concentrations 
measured in the study (Figure 6). Simulations of serum concentrations were in good 
agreement with experimental data. Clearance of PFOA from the serum is much faster in 
female rats than male rats – this is seen in the experiments conducted by Kemper and 
elsewhere in the literature (Vanden Heuvel et al., 1991; Andersen et al., 2006; Tatum-Gibbs 
et al., 2011). The model was able to accurately describe this sex-specific clearance behavior 
following IV administration of PFOA.
Experimental time-course serum, urine, and feces data following oral administration of 0.1, 
5.0, and 25.0 mg/kg body weight (Kemper, 2003) were available for evaluation of the 
female rat model (Figure 7). Model simulations of serum concentration and the cumulative 
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percent of the dose in the urine and feces for 5.0 and 25.0 mg/kg body weight doses were 
compared to the data reported in the study. Simulated serum concentrations were in good 
agreement with experimental data with respect to the peak concentrations and the overall 
shape of the serum concentration curve (Fig. 7A, 7C). As with the simulation of the IV data, 
the model was able to describe successfully the sex-specific clearance of PFOA following 
oral gavage exposures at all doses. Comparison of the predicted cumulative amount of 
PFOA in the urine to measured data also showed good agreement (Fig. 7B, 7D). The model 
successfully described the measured amounts in the urine and the overall kinetics of urinary 
clearance as indicated by the shape of the curve. The cumulative amount of PFOA in the 
feces was under predicted by the model in the lower dose tested (data not shown).
Quantitative Model Evaluation
RMSE values were calculated for simulations of each experimental dataset with more than 
one experimental data point. Results are available in table 5. Comparison of RMSE values 
for simulation of experimental time-course serum data for male and female experiments 
conducted at the same dose were similar. This suggests that the model predicted 
experimental serum data in the male rat equally well as experimental data in the female rat. 
Comparison of RMSE values for simulation of the measured cumulative percent of the dose 
to appear in the urine for experiments conducted at the same dose were lower in simulation 
for the male rat than the female rat, suggesting that the model predictions more closely fit 
time-course urine data for the male than the female. Conversely, comparisons of the 
cumulative percent of the dose to appear in the feces for experiments conducted at the same 
dose suggest that the model more accurately predicted feces data for the female rat.
Impact of Dose on Renal Clearance
Male Rat—Our model predictions indicated that the amount of PFOA transported from the 
blood into the filtrate by the basolateral membrane transporters is linear in a dose range from 
0.1 to 40 mg/kg body weight (Figure 8A). Similarly, the predicted amount of PFOA 
transported from the filtrate back into the proximal tubules also appears to be linear in a 
dose range from 0.1 to 40 mg/kg body weight. At doses higher than 40 mg/kg body weight 
the amount of PFOA transported by both basolateral and apical membrane transporter 
gradually decreases, suggesting saturation of these mechanisms.
Measurements of serum half-life for PFOA in male rats are reported to range from 96 – 216 
hours (Lau et al., 2004; Harada et al., 2005; Kudo et al., 2007). Our model predictions are in 
agreement with these estimates and with reports in the literature that suggest that serum 
clearance of PFOA may increase (causing half-life to decrease) as dose increases and 
transporters become fully saturated (Cui et al., 2010). In an exposure dose-range from 0.1 to 
40 mg/kg body weight, our model predicts that half-life decreases linearly from 152 to 88 
hours (Figure 9A).
When Vmax parameters for the transporters (Vmax_baso and Vmax_apical) expressed in the 
proximal tubule cells are set to zero, effectively turning them off, the predicted serum half-
life is 3.3 hours at all doses (Figure 9A). Simulations of exposures to very high doses 
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(greater than 200 mg/kg body weight) with transporters turned on predicted similar serum 
half-lives, again suggesting that transporters can be saturated at high doses.
Female Rat—Simulations with the female rat model indicated that the amount of PFOA 
transported from the blood into the filtrate by the basolateral membrane transporters is linear 
in a dose range from 0.1 to 10 mg/kg body weight and became non-linear at a lower dose 
than in the male rat (Figure 8B). At doses higher than 10 mg/kg body weight the amount of 
PFOA transported by both basolateral and apical membrane transporter gradually decreases, 
suggesting saturation of these mechanisms.
Serum half-life for PFOA decreased linearly from 9.3 – 5.0 hours at doses of 0.1 – 10 mg/kg 
body weight (Figure 9B). These predictions are in agreement with estimates from 
experimental studies that report the serum half-life for PFOA in the female rat to be 1.92–24 
hours (Han et al., 2003; Lau et al., 2004; Harada et al., 2005). When Vmax parameters 
(Vmax_baso and Vmax_apical) were set to zero to turn off transporter activity, the predicted 
serum half-life was 4.4 hours at all doses. Similar to what was seen in the male rat, 
simulations of exposures to high doses (greater than 30 mg/kg body weight) with 
transporters turned on predicted the same serum half-life (Fig. 9B).
Sensitivity Analysis
A normalized sensitivity analysis was performed for 1.0 and 25.0 mg/kg body weight single 
oral doses in the male and female rat. Table 6 gives model parameters determined to be 
sensitive with absolute sensitivity coefficients greater than 0.1 or 1.0 in the time course of 
PFOA serum concentrations over a period of 530 hours following simulation of PFOA 
administration at either dose level.
In general, parameters that were found to be sensitive in the male rat model were also found 
to be sensitive in the female rat model. However, VPTCC, VplasC, MKC, keffluxC, and kdif 
were found to be sensitive in the female rat model but not in the male rat model. 
Additionally, a greater number of parameters in the female rat model appear to impact the 
PFOA serum concentrations to a large extent (absolute sensitivity coefficients greater than 
1.0) than in the male rat model. Of particular note, the female rat model appears to be much 
more sensitive to GFRC than is the male rat model.
The calculated sensitivity coefficients were not very different across simulations at the two 
different doses. Parameters that were identified as sensitive (or not sensitive) in the 
simulation of administration of 1.0 mg/kg body weight were similarly identified in the 
simulation of administration of 25.0 mg/kg body weight. This analysis provides a hierarchy 
useful to decide which parameter values must be measured most carefully (Evans et al., 
1994). Additional sensitivity analysis data is available in the supplementary materials.
Discussion
The model described here aims to explore the role of kidney transporters on the renal 
reabsorption and excretion of PFOA in the adult rat. This work builds upon past modeling 
efforts that have explored similar questions. A biologically-based compartmental model for 
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PFOA administration in Cynomolgus monkeys (Andersen et al., 2006) and a PBPK model 
for PFOA administration in the adult rat (Loccisano et al., 2012) have demonstrated the 
importance of saturable renal reabsorption in the pharmacokinetic behavior of PFOA in the 
rat. The PBPK model developed by Loccisano and colleagues used in vitro derived Km 
values for Oatp1a1 to begin to describe transporter kinetics; however, sufficient data were 
not available to support the inclusion of complete physiological descriptions of transporter-
mediated PFOA transport. The availability of new in vitro data describing the kinetics of 
Oatp1a1, Oat1, and Oat3 mediated PFOA uptake has made it possible to use in vitro to in 
vivo extrapolation to include physiologically-based descriptions of renal excretion and 
reabsorption. This has allowed for a deeper exploration of the sex-specific serum clearance 
observed in the adult rat.
In vitro studies are frequently used to evaluate the uptake of compounds in various cellular 
systems (Giacomini et al., 2010; Feng et al., 2014; Hsu et al., 2014). In vitro protein 
transporter kinetic data can be scaled to approximate in vivo pharmacokinetic parameters 
(Bosgra et al., 2014). This in vitro to in vivo extrapolation of transporter data has been 
shown to be useful for deriving pharmacokinetic parameters for use in PBPK models 
elsewhere in the literature (Bosgra et al., 2014). The results of our model evaluation indicate 
that in vitro to in vivo extrapolated descriptions of the apical and basolateral membrane 
transporters are able to successfully describe and predict time-course PFOA-serum 
concentrations, liver concentrations, as well as the cumulative percent of the administered 
dose in the urine in the male and female rat.
The model over predicted the cumulative percentage of PFOA in the feces in some instances 
and under predicted in others. However, feces is a very small contributor to PFOA excretion, 
thus, less priority was given to feces predictions when evaluating the model. Johnson et al, 
previously suggested that hepatic accumulation of PFOA may be related to enterohepatic 
recirculation based on observations that treatment of rats with cholestyramine increased 
fecal elimination (Johnson, 1984). However, cholestyramine was later shown to increase 
bile excretion into the gut, and thereby increase fecal elimination (Trautwein et al., 1999). 
Given that the observed increase in fecal elimination was likely a result of increased biliary 
excretion rather than enterohepatic recirculation, enterohepatic recirculation was not 
considered a significant contributor to PFOA kinetics in the rat and was not included in the 
model.
In the male rat model, where PFOA is thought to be more readily reabsorbed into the 
systemic circulation, the amount of PFOA moved from the circulation to the filtrate via GFR 
is comparable to the amount of PFOA moved from the filtrate back into the proximal tubule 
cells via the apical transporters. In the female rat model, where the apical membrane 
transporters are thought to be less active, the amount of PFOA moved into the filtrate via 
GFR is much larger than the amount of PFOA moved from the circulation into the proximal 
tubules via the basolateral transporters. This suggests that, in the female rat, without 
significant renal reabsorption of PFOA, GFR is an important driver of PFOA excretion. This 
analysis is supported by the sensitivity analysis, which suggests that the female rat model is 
more sensitive to GFRC than is the male rat model.
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The model was able to predict serum half-lives in both the male and female rat that 
correspond to estimates reported in experimental studies. These findings support the 
conclusions of previous computational models for PFOA in the rat that saturable renal 
reabsorption of PFOA is an important driver of serum concentrations in the male and female 
rat. In addition, our results suggest that in vitro to in vivo extrapolation of the parameters 
that describe transporter kinetics is a viable method for parameterization of PBPK models. 
Additional exploration of transporter kinetics in in vitro systems is needed to expand on this 
work.
Structurally, our male and female rat models are identical. We have shown that by 
modifying only sex-specific physiological parameters (GFR and BW) and the parameters 
that describes the activity of the apical and basolateral membrane transporters (RAFapi and 
RAFbaso), our model was able to successfully describe sex-specific serum clearance in the 
rat. Further, our model was able to accurately predict the serum half-life in both the male 
and female rat. These results support the hypothesis that the observed sex differences in 
serum clearance and half-life are a product of differential expression and activity of the 
transporters that mediate PFOA excretion and reabsorption – specifically, Oat1, Oat3, and 
Oatp1a1.
Evaluation of serum half-life following simulation of administration of a wide range of 
doses reveals that the model is also capable of describing transporter saturation. In both the 
male and female rat models, comparison of predicted serum half-life at very high doses, 
when transporters would presumably be saturated are very similar to predicted serum half-
lives when model simulations are run with Vmax_baso and Vmax_apical equal to zero. 
Essentially, our model predicts that the serum half-life when transporters are saturated is the 
same as when the transporters are turned off. This non-linear pharmacokinetic response has 
also been observed in the mouse (Lou et al., 2009). Further, our model demonstrates that 
when the transporters involved in renal excretion and reabsorption are turned off or 
saturated, serum half-life is no longer sex specific. In addition to the previously mentioned 
results, these data support the hypothesis that the saturable renal reabsorption and renal 
clearance in the rat is driven by the expression and activity of the apical and basolateral 
membrane transporters in the proximal tubule cells. This data also supports the hypothesis 
that sex-specific pharmacokinetic behavior in the rat is primarily a product of sex-specific 
OAT expression and activity in the proximal tubule cells.
Historically, PBPK models have not been parameterized to specifically include expansive 
descriptions of transporter kinetics; however, recent models are beginning to be developed 
to predict transporter-mediated chemical disposition (Feng et al., 2014). Given the role that 
transporters play in the ultimate distribution and excretion of chemicals in the body, 
incorporation of data driven, physiologically-based descriptions of these processes has the 
potential to improve the utility of PBPK models for sex, species, and life-stage 
extrapolation, especially for compounds like PFOA.
Ultimately, this work could be improved with in vitro studies more specifically tailored to 
generate data for PBPK modeling purposes. For example, relative activity factors were only 
available for the human orthologues of basolateral transporters. Data collected using the 
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same cell type (HEK293 cell) as those used in the kinetic studies of these transporters and in 
rat kidney slices would have resulted in greater certainty in this parameter value.
Transporter expression and activity in the proximal tubule cells have been shown to be the 
primary driver of sex-specific and species-specific serum clearance of PFOA (Andersen et 
al., 2006). Our model successfully incorporates sex-specific descriptions of these 
transporters. With additional in vitro data describing the kinetics of the transporters that are 
expressed in human proximal tubule cells, this model can be scaled up to describe 
transporter-mediated renal secretion and reabsorption of PFOA in humans. A human PBPK 
model for PFOA with transporter-specific descriptions could be used to evaluate the impact 
of polymorphic variability of OATs in human populations on PFOA-serum concentrations 
using Monte Carlo analysis. This rat model and the future planned work to expand upon 
these efforts have the potential to contribute to the understanding of the effects of exposure 
to PFOA.
This evidence-based model supports the hypothesis that sex-specific serum half-lives for 
PFOA are driven by the expression and activity of transporters in the kidney and 
demonstrates that in vitro to in vivo extrapolation can be used to incorporate transporter-
specific descriptions in PBPK models.
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Figure 1. Structure of PBPK model for PFOA in the adult rat
Chemical is introduced via oral gavage into the stomach or intravenous injection into the 
plasma.
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Figure 2. Model calibration of the male rat model, with IV exposure data
Comparisons of the predicted and measured serum concentrations resulting from IV 
exposure to 1.0 mg/kg body weight PFOA. Predictions shown as solid line, measured data 
shown as black circles.
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Figure 3. Model calibration of the male and female rat models with oral gavage exposure data
Comparisons of the predicted and measured serum concentrations and the cumulative 
percent of the dose in the urine resulting from oral exposure to 1.0 mg/kg body weight 
PFOA. Simulations in the male rat model shown in panels A and B. Simulations in the 
female rat model shown in panels C and D. Predictions shown as solid lines, measured data 
shown as black circles.
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Figure 4. Model evaluation with time course data resulting from IV exposure in the male rat
Comparisons of the predicted and measured serum (4A) and liver (4B) concentrations 
resulting from high (16.0 mg/kg body weight) and low (0.041 mg/kg body weight) dose IV 
exposures. High exposure dose data shown as solid line (predicted) and black circle 
(measured). Low exposure dose data shown as dashed line (predicted) and black cross 
(measured).
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Figure 5. Model evaluation with time course data resulting from oral gavage exposure in the 
male rat
Comparisons of the predicted and measured serum concentrations and the cumulative 
percent of the dose in the urine resulting from oral exposure to 5.0 (panels A and B) or 25.0 
(panels C and D) mg/kg body weight PFOA. Predictions shown as solid lines, measured data 
shown as black circles.
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Figure 6. Model evaluation with time course data resulting from IV exposure in the female rat
Comparisons of the predicted and measured serum concentrations resulting from IV 
exposure to 1.0 mg/kg body weight PFOA. Predictions shown as solid line, measured data 
shown as black circles.
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Figure 7. Model evaluation with time course data resulting from oral gavage exposure in the 
female rat
Comparisons of the predicted and measured serum concentrations and the cumulative 
percent of the dose in the urine resulting from oral exposure to 5.0 (panels A and B) or 25.0 
(panels C and D) mg/kg body weight PFOA. Predictions shown as solid lines, measured data 
shown as black circles.
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Figure 8. Evaluation of the impact of dose on transporter activity in the male and female rat 
models
Model predicted mass of PFOA transported by basolateral (dashed line – right Y-axis) and 
apical (solid line – left y-axis) membrane transporters. Black circles and crosses represent 
actual data points. Male data shown in panel A, female data shown in panel B.
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Figure 9. Evaluation of the impact of dose on serum half-life in the male and female rat models
Model predicted serum half-life. Solid line – transporters turned on, dashed line – 
transporters turned off. Black circles and crosses represent actual data points. Male data 
shown in panel A, female data shown in panel B.
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Table 2
Physiological parameters for PBPK model for PFOA in adult rats.
Parameter Definition Units Value Source
QCC cardiac output L/h/kg0.75 14.0 Brown et al., 1997
QLC fraction blood flow to liver Unitless 0.183 Brown et al., 1997
QKC fraction blood flow to kidney Unitless 0.141 Brown et al., 1997
Htc Hematocrit Unitless 0.46 Davies and Morris, 1993Brown et al., 1997
VplasC fraction volume of plasma L/kg BW 0.0312 Davies and Morris, 1993Brown et al., 1997
VLC fraction volume of liver L/kg BW 0.035 Brown et al., 1997
VKC fraction volume of kidney L/kg BW 0.0084 Brown et al., 1997
VfilC fraction volume of filtrate L/kg BW 8.40 × 10−4 10% kidney volume
VPTCC fraction volume of proximal tubule cells (PTC) L/g kidney 1.35 × 10
−4
calculated based on 60 million PTC/gram kidney 
(Hsu et al., 2014), 1 PTC = 2250 um3 (Milo et 
al., 2010)
Protein amount of protein in proximal tubule cells
mg protein/proximal 
tubule cell 2.0 ×10
−6 Addis et al., 1936
GFRC
glomerular filtration rate (male) L/hr/kg kidney 62.1 Corley et al., 2005
glomerular filtration rate (female) L/hr/kg kidney 41.04 Corley et al., 2005
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Table 3
Chemical specific parameters for adult rat PFOA PBPK model.
Parameter Definition Units Value Source
Free free fraction of PFOA in plasma unitless 0.09 Fit to Kemper, Experiment 6b and 6b
Vmax_basoC Vmax of basolateral transporters measured in in vitro studies (average of Oat1 and Oat3) mg/h/kg BW
0.75 0.04 Calculated from Nakagawa et al., 2007
Km_baso Km of basolateral transporters (Oat1 and Oat3) ug/mL 27.20 Nakagawa et al., 2007
Vmax_apicalC Vmax of apical transporters measured in in vitro studies (Oatp1a1) mg/h/kg BW
0.75 0.947 Calculated from Nakagawa et al., 2007
Km_apical Km of apical transporters (Oatp1a1) ug/mL 52.3 Weaver et al., 2010
RAFapi
relative activity factor of apical transporters (male) unitless 35.0 Fit to Kemper, Experiment 6b
relative activity factor of apical transporters (female) unitless 0.001356 Fit to Kemper, Experiment 6a
RAFbaso
relative activity factor of basolateral transporters 
(male) unitless 4.07 Fit to Kemper, Experiment 6b
relative activity factor of basolateral transporters 
(female) unitless 0.01356 Fit to Kemper, Experiment 6a
PL liver:blood partition coefficient 2.2 Kudo et al., 2007
PK kidney:blood partition coefficient 1.05 Kudo et al., 2007
PR Rest of body:blood partition coefficient 0.11 Kudo et al., 2007
k0c rate of absorption of PFOA in stomach /hr/kg0.25 1.0
Fit to Kemper, Experiment 1 
and Experiment 6a
kabsc rate of absorption of PFOA in small intestines /hr/kg0.25 2.12
Fit to Kemper, Experiment 1 
and Experiment 6a
kunabsc rate of unabsorbed dose to appear in feces /hr/kg0.25 7.06 × 10−5
Fit to Kemper, Experiment 1 
and Experiment 6a
keffluxc rate of clearance of PFOA from proximal tubule cells into blood /hr/kg
0.25 2.49 Fit to Kemper, Experiment 6a and 6b
kbilec biliary elimination rate /hr/kg0.25 0.004
Fit to Kemper, Experiment 1 
and Experiment 6a
kurinec urinary elimination rate /hr/kg0.25 1.6
Fit to Kemper, Experiment 6a 
and 6b
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Table 4
Initial and Calibrated Parameter Values
Parameter Units Initial Value Source of Initial Value Calibrated Value
Free unitless 0.006 Loccisano, 2012 0.09
RAFapi, male unitless 0.01356 Yamada, 2007 35
RAFapi, female unitless 0.01356 Yamada, 2007 0.001356
RAFbaso, male unitless 0.01356 Yamada, 2007 4.07
RAFbaso, female unitless 0.01356 Yamada, 2007 0.01356
k0c /hr/kg0.25 1.0 - 1.0
Kabsc /hr/kg0.25 31.3 Loccisano, 2012 2.12
kunabsc /hr/kg0.25 0.001 Loccisano, 2012 7.06 × 10−5
keffluxc /hr/kg0.25 0 - 2.49
Kbilec /hr/kg0.25 0.35 Loccisano, 2012 0.004
Kurinec /hr/kg0.25 0.1 Loccisano, 2012 1.6













Worley and Fisher Page 32
Table 5
Root Mean Squared Errors for Simulations of Male and Female Rat Experiments
Experiment Dose (mg/kg) Male Female
Kemper Experiment 1 - Urine 1.0 6.36 20.86
Kemper Experiment 2 - Urine 5.0 6.75 16.53
Kemper Experiment 3 - Urine 25.0 4.48 15.99
Kemper Experiment 1 - Feces 1.0 22.75 0.52
Kemper Experiment 2 - Feces 5.0 31.81 3.80
Kemper Experiment 3 - Feces 25.0 22.54 0.61
Kemper Experiment 5 - Serum 0.1 0.06 0.17
Kemper Experiment 6 - Serum, oral 1.0 0.89 0.78
Kemper Experiment 6 - Serum, IV 1.0 1.47 0.75
Kemper Experiment 7 - Serum 5.0 5.69 2.98
Kemper Experiment 8 - Serum 25.0 9.00 18.88
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Table 6
Sensitive Model Parameters.
Physiological Parameters Partition Coefficients Chemical Specific Model Parameters
Male Rat BW, GFRC, protein, VfilC, VLC, HTC, QKC, 
QLC, QCC PR, PL
kurinec, kbilec, k0c, kabsc, RAFapi, 
Km_apical, Vmax_apical_invitro, Free, MW
Female Rat BW, GFRC, protein, VPTCC, VfilC, VLC, 
VplasC, HTC, QKC, QLC, QCC, MKC PR, PL
kurinec, kbilec, keffluxc, k0c, kabsc, kdif, 
RAFapi, Km_apical, Vmax_apical_invitro, 
Free, MW
Parameters with absolute sensitivity coefficients greater than 1.0 are highlighted in bold.
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